AU2016307882A1 - Compositions comprising a PI3K inhibitor and an HDAC inhibitor - Google Patents
Compositions comprising a PI3K inhibitor and an HDAC inhibitor Download PDFInfo
- Publication number
- AU2016307882A1 AU2016307882A1 AU2016307882A AU2016307882A AU2016307882A1 AU 2016307882 A1 AU2016307882 A1 AU 2016307882A1 AU 2016307882 A AU2016307882 A AU 2016307882A AU 2016307882 A AU2016307882 A AU 2016307882A AU 2016307882 A1 AU2016307882 A1 AU 2016307882A1
- Authority
- AU
- Australia
- Prior art keywords
- formula
- alkyl
- composition
- methyl
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- FLZWKBQXFJJTQN-UHFFFAOYSA-N CN(CC1)CC11CCN(Cc2cnc3[o]c4c(N5CCOCC5)nc(-c5cccc6c5cc[nH]6)nc4c3c2)CC1 Chemical compound CN(CC1)CC11CCN(Cc2cnc3[o]c4c(N5CCOCC5)nc(-c5cccc6c5cc[nH]6)nc4c3c2)CC1 FLZWKBQXFJJTQN-UHFFFAOYSA-N 0.000 description 3
- IMRWILPUOVGIMU-UHFFFAOYSA-N Brc1ncccc1 Chemical compound Brc1ncccc1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 1
- POOPWPIOIMBTOH-UHFFFAOYSA-O C(C1)C2OC1C[NH2+]C2 Chemical compound C(C1)C2OC1C[NH2+]C2 POOPWPIOIMBTOH-UHFFFAOYSA-O 0.000 description 1
- HIHJTEJYORZWIL-ROUUACIJSA-N C(c(cc12)cnc1[o]c1c2nc(-c2c(cc[nH]3)c3ccc2)nc1N1CCOCC1)N1[C@@H](C2)CO[C@@H]2C1 Chemical compound C(c(cc12)cnc1[o]c1c2nc(-c2c(cc[nH]3)c3ccc2)nc1N1CCOCC1)N1[C@@H](C2)CO[C@@H]2C1 HIHJTEJYORZWIL-ROUUACIJSA-N 0.000 description 1
- ZQTGRUPLSCXUEJ-UHFFFAOYSA-N C(c(cc12)cnc1[o]c1c2nc(-c2cccc3c2cc[nH]3)nc1N1CCOCC1)N1CCC2(COC2)CC1 Chemical compound C(c(cc12)cnc1[o]c1c2nc(-c2cccc3c2cc[nH]3)nc1N1CCOCC1)N1CCC2(COC2)CC1 ZQTGRUPLSCXUEJ-UHFFFAOYSA-N 0.000 description 1
- HIHJTEJYORZWIL-QZTJIDSGSA-N C(c(cc12)cnc1[o]c1c2nc(-c2cccc3c2cc[nH]3)nc1N1CCOCC1)N1[C@H](C2)CO[C@H]2C1 Chemical compound C(c(cc12)cnc1[o]c1c2nc(-c2cccc3c2cc[nH]3)nc1N1CCOCC1)N1[C@H](C2)CO[C@H]2C1 HIHJTEJYORZWIL-QZTJIDSGSA-N 0.000 description 1
- RECARUFTCUAFPV-UHFFFAOYSA-N C1OCC11CCNCC1 Chemical compound C1OCC11CCNCC1 RECARUFTCUAFPV-UHFFFAOYSA-N 0.000 description 1
- DIQOUXNTSMWQSA-WHFBIAKZSA-N C1[C@@H]2OC[C@H]1NC2 Chemical compound C1[C@@H]2OC[C@H]1NC2 DIQOUXNTSMWQSA-WHFBIAKZSA-N 0.000 description 1
- DIQOUXNTSMWQSA-RFZPGFLSSA-N C1[C@H]2OC[C@@H]1NC2 Chemical compound C1[C@H]2OC[C@@H]1NC2 DIQOUXNTSMWQSA-RFZPGFLSSA-N 0.000 description 1
- PYICKTFFRZTUGP-UHFFFAOYSA-N CC(c1ccc(CN(c2nnc(C)[s]2)c2ncccc2)cc1)=O Chemical compound CC(c1ccc(CN(c2nnc(C)[s]2)c2ncccc2)cc1)=O PYICKTFFRZTUGP-UHFFFAOYSA-N 0.000 description 1
- SEXCXAIQIMWSBF-UHFFFAOYSA-N CN(CC1)CC11CCNCC1 Chemical compound CN(CC1)CC11CCNCC1 SEXCXAIQIMWSBF-UHFFFAOYSA-N 0.000 description 1
- WNHMQEHZERGFEN-UHFFFAOYSA-N CN(CC1)CC11CN(Cc2cnc3[o]c4c(N5CC(c(c6c7cc[nH]6)ccc7-c(nc6N7CCOCC7)nc7c6[o]c6c7cc(CN7CC(CC8)OC8C7)cn6)OCC5)nc(-c5cccc6c5cc[nH]6)nc4c3c2)CC1 Chemical compound CN(CC1)CC11CN(Cc2cnc3[o]c4c(N5CC(c(c6c7cc[nH]6)ccc7-c(nc6N7CCOCC7)nc7c6[o]c6c7cc(CN7CC(CC8)OC8C7)cn6)OCC5)nc(-c5cccc6c5cc[nH]6)nc4c3c2)CC1 WNHMQEHZERGFEN-UHFFFAOYSA-N 0.000 description 1
- OQHQOOLVQDEIGL-UHFFFAOYSA-N CN(CC1)CC11CNCC1 Chemical compound CN(CC1)CC11CNCC1 OQHQOOLVQDEIGL-UHFFFAOYSA-N 0.000 description 1
- OULKIPPQVXRBPY-UHFFFAOYSA-N CN1CCC2(CNCC2)CC1 Chemical compound CN1CCC2(CNCC2)CC1 OULKIPPQVXRBPY-UHFFFAOYSA-N 0.000 description 1
- IJJGOAIJDMYZJR-UHFFFAOYSA-N CN1COCCC1 Chemical compound CN1COCCC1 IJJGOAIJDMYZJR-UHFFFAOYSA-N 0.000 description 1
- XFLJTZVMJDWKPC-UHFFFAOYSA-N Cc1n[s]c(Nc(cc2)ncc2F)n1 Chemical compound Cc1n[s]c(Nc(cc2)ncc2F)n1 XFLJTZVMJDWKPC-UHFFFAOYSA-N 0.000 description 1
- JPBLHOJFMBOCAF-UHFFFAOYSA-N Nc1nc(cccc2)c2[o]1 Chemical compound Nc1nc(cccc2)c2[o]1 JPBLHOJFMBOCAF-UHFFFAOYSA-N 0.000 description 1
- DZRIXLUFXJVNSI-UHFFFAOYSA-N O=Cc(cc12)cnc1[o]c1c2nc(-c2c(cc[nH]3)c3ccc2)nc1N1CCOCC1 Chemical compound O=Cc(cc12)cnc1[o]c1c2nc(-c2c(cc[nH]3)c3ccc2)nc1N1CCOCC1 DZRIXLUFXJVNSI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1514756.4 | 2015-08-19 | ||
| GBGB1514756.4A GB201514756D0 (en) | 2015-08-19 | 2015-08-19 | Compound and method of use |
| PCT/GB2016/052571 WO2017029514A1 (en) | 2015-08-19 | 2016-08-19 | Compositions comprising a pi3k inhibitor and an hdac inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2016307882A1 true AU2016307882A1 (en) | 2018-03-08 |
Family
ID=54258855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016307882A Abandoned AU2016307882A1 (en) | 2015-08-19 | 2016-08-19 | Compositions comprising a PI3K inhibitor and an HDAC inhibitor |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20180243317A1 (enExample) |
| EP (2) | EP3337484A1 (enExample) |
| JP (1) | JP2018528192A (enExample) |
| KR (1) | KR20180069788A (enExample) |
| CN (1) | CN108348523A (enExample) |
| AU (1) | AU2016307882A1 (enExample) |
| BR (1) | BR112018003026A2 (enExample) |
| CA (1) | CA2995991A1 (enExample) |
| GB (1) | GB201514756D0 (enExample) |
| HK (1) | HK1251466A1 (enExample) |
| IL (1) | IL257521A (enExample) |
| MX (1) | MX2018001990A (enExample) |
| SG (1) | SG10201913619XA (enExample) |
| WO (1) | WO2017029514A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2467387T3 (pl) | 2009-08-20 | 2015-08-31 | Karus Therapeutics Ltd | Tricykliczne związki heterocykliczne jako inhibitory kinazy 3-fosfoinozytydu |
| GB201204125D0 (en) | 2012-03-08 | 2012-04-25 | Karus Therapeutics Ltd | Compounds |
| SMT201800501T1 (it) | 2013-05-10 | 2018-11-09 | Karus Therapeutics Ltd | Nuovi inibitori di istone deacetilasi |
| GB201402431D0 (en) | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
| GB201514751D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| GB201514758D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Formulation |
| GB201514754D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| GB201514760D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds and method of use |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| US10357493B2 (en) | 2017-03-10 | 2019-07-23 | Selenity Therapeutics (Bermuda), Ltd. | Metalloenzyme inhibitor compounds |
| EP3737362B1 (en) * | 2018-01-12 | 2025-10-15 | Kdac Therapeutics, Inc. | Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer |
| US11952362B2 (en) | 2018-07-23 | 2024-04-09 | The Regents Of The University Of California | Compositions and methods for treating epigenetic disease |
| KR102162744B1 (ko) * | 2018-09-18 | 2020-10-07 | 인제대학교산학협력단 | 프라시노스타트를 포함하는 염증성 장질환 치료용 약학 조성물 |
| GB201909468D0 (en) * | 2019-07-01 | 2019-08-14 | Karus Therapeutics Ltd | Compounds for treating cancer |
| GB201913121D0 (en) * | 2019-09-11 | 2019-10-23 | Seald As | Compositions and methods for treatment of cholangiocarcinoma |
| WO2021113401A2 (en) * | 2019-12-02 | 2021-06-10 | The Regents Of The University Of Colorado, A Body Corporate | Histone deacytlase 6 modulation of titin protein mediated cardiac tissue stiffness and method for same |
| US20230038929A1 (en) | 2019-12-05 | 2023-02-09 | Verge Analytics, Inc. | Fused Tricyclic Heterocyclic Compounds and Uses Thereof |
| CR20220325A (es) | 2019-12-20 | 2022-08-19 | Tenaya Therapeutics Inc | Fluoroalquil-oxadiazoles y sus usos |
| CN111686097A (zh) * | 2020-07-31 | 2020-09-22 | 上海交通大学医学院附属第九人民医院 | Lmk235在抑制瘢痕形成的药物中的应用 |
| WO2022169882A1 (en) | 2021-02-03 | 2022-08-11 | Verge Analytics, Inc. | Methods and treatment of viral infection caused by sars-cov-2 |
| CA3216768A1 (en) | 2021-05-04 | 2022-11-10 | Jin Yang | 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef |
| CN114890989B (zh) * | 2022-05-25 | 2024-03-22 | 广东晨康生物科技有限公司 | 一种含氮衍生物为Linker的HDAC8降解剂其制备方法和应用 |
| CN120916756A (zh) * | 2023-03-03 | 2025-11-07 | 伊昂克图拉股份有限公司 | 用于治疗血液恶性肿瘤的罗吉诺利西布与hdac抑制剂的组合 |
| CN116987073A (zh) * | 2023-08-03 | 2023-11-03 | 嘉兴学院 | 一种PI3Kα/HDAC6亚型选择性双重抑制剂及其应用 |
| CN118750492A (zh) * | 2024-07-15 | 2024-10-11 | 中日友好医院(中日友好临床医学研究所) | 一种hdac6高选择抑制剂cay10603的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6905669B2 (en) | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| CA2672270A1 (en) * | 2006-12-15 | 2008-06-26 | Gennadi V. Glinksy | Treatments of therapy resistant diseases and drug combinations for treating the same |
| PL2467387T3 (pl) * | 2009-08-20 | 2015-08-31 | Karus Therapeutics Ltd | Tricykliczne związki heterocykliczne jako inhibitory kinazy 3-fosfoinozytydu |
| SMT201800501T1 (it) | 2013-05-10 | 2018-11-09 | Karus Therapeutics Ltd | Nuovi inibitori di istone deacetilasi |
| JP6626437B2 (ja) * | 2013-10-08 | 2019-12-25 | アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | ヒストンデアセチラーゼ阻害剤とＨｅｒ２阻害剤またはＰＩ３Ｋ阻害剤のいずれかの組み合わせ |
| US20150105383A1 (en) | 2013-10-10 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | HDAC Inhibitors, Alone Or In Combination With PI3K Inhibitors, For Treating Non-Hodgkin's Lymphoma |
| GB201402431D0 (en) * | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
-
2015
- 2015-08-19 GB GBGB1514756.4A patent/GB201514756D0/en not_active Ceased
-
2016
- 2016-08-19 AU AU2016307882A patent/AU2016307882A1/en not_active Abandoned
- 2016-08-19 MX MX2018001990A patent/MX2018001990A/es unknown
- 2016-08-19 SG SG10201913619XA patent/SG10201913619XA/en unknown
- 2016-08-19 HK HK18110946.4A patent/HK1251466A1/zh unknown
- 2016-08-19 WO PCT/GB2016/052571 patent/WO2017029514A1/en not_active Ceased
- 2016-08-19 BR BR112018003026A patent/BR112018003026A2/pt not_active IP Right Cessation
- 2016-08-19 CA CA2995991A patent/CA2995991A1/en not_active Abandoned
- 2016-08-19 US US15/753,356 patent/US20180243317A1/en not_active Abandoned
- 2016-08-19 EP EP16756762.7A patent/EP3337484A1/en not_active Withdrawn
- 2016-08-19 EP EP18202398.6A patent/EP3456355A1/en not_active Withdrawn
- 2016-08-19 JP JP2018508715A patent/JP2018528192A/ja not_active Withdrawn
- 2016-08-19 CN CN201680058695.6A patent/CN108348523A/zh active Pending
- 2016-08-19 KR KR1020187007811A patent/KR20180069788A/ko not_active Withdrawn
-
2018
- 2018-02-14 IL IL257521A patent/IL257521A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018001990A (es) | 2018-06-19 |
| BR112018003026A2 (pt) | 2018-09-18 |
| CA2995991A1 (en) | 2017-02-23 |
| US20180243317A1 (en) | 2018-08-30 |
| SG10201913619XA (en) | 2020-03-30 |
| IL257521A (en) | 2018-04-30 |
| GB201514756D0 (en) | 2015-09-30 |
| EP3337484A1 (en) | 2018-06-27 |
| KR20180069788A (ko) | 2018-06-25 |
| CN108348523A (zh) | 2018-07-31 |
| HK1251466A1 (zh) | 2019-02-01 |
| WO2017029514A1 (en) | 2017-02-23 |
| EP3456355A1 (en) | 2019-03-20 |
| JP2018528192A (ja) | 2018-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016307882A1 (en) | Compositions comprising a PI3K inhibitor and an HDAC inhibitor | |
| EP2994465B1 (en) | Novel histone deacetylase inhibitors | |
| ES2798150T3 (es) | Derivado de quinolina | |
| ES2673278T3 (es) | Compuestos heterocíclicos tricíclicos como inhibidores de la fosfoinositol 3-cinasa | |
| CA3025722A1 (en) | Combinations comprising histone deacetylase inhibitors | |
| AU2013343291B2 (en) | Novel histone deacetylase inhibitors and their use in therapy | |
| US10442815B2 (en) | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | |
| AU2015340303B2 (en) | Polyheteroaryl histone deacetylase inhibitors and their use in therapy | |
| CN113786409A (zh) | 包含磷酸肌醇3-激酶抑制剂和第二抗增殖剂的组合物 | |
| HK1222660B (en) | Novel histone deacetylase inhibitors | |
| HK40065474A (en) | Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |